MEDIFAST INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $385.8M | $602.5M | $1.1B | $1.6B | $1.5B |
| Cost of revenue | $110.6M | $157.8M | $296.2M | $458.2M | $398.5M |
| Gross profit | $275.2M | $444.6M | $775.9M | $1.1B | $1.1B |
| Selling, general & administrative | $289.4M | $441.7M | $649.4M | $955.6M | $911.4M |
| Research and development | $4.3M | $4.6M | $4.6M | $4.5M | $4.4M |
| Operating income | -$14.2M | $2.9M | $126.4M | $184.8M | $216.2M |
| Pretax income | -$5.6M | $3.8M | $128.8M | $184.1M | $216.1M |
| Income tax expense | $13.0M | $1.7M | $29.4M | $40.5M | $52.1M |
| Net income | -$18.7M | $2.1M | $99.4M | $143.6M | $164.0M |
| Balance Sheet | |||||
| Cash and equivalents | $89.3M | $90.9M | $94.4M | $87.7M | $104.2M |
| Current assets | $201.7M | $214.4M | $224.0M | $222.8M | $306.9M |
| Total assets | $248.0M | $284.2M | $309.9M | $316.2M | $398.3M |
| Current liabilities | $43.0M | $64.2M | $92.3M | $140.9M | $169.8M |
| Total liabilities | $49.1M | $74.1M | $108.4M | $161.2M | $195.9M |
| Stockholders' equity | $198.9M | $210.1M | $201.5M | $155.0M | $202.5M |
| Cash Flow Statement | |||||
| Cash from operations | $6.9M | $24.5M | $147.7M | $194.6M | $94.5M |
| Depreciation and amortization | $14.2M | $12.7M | $13.1M | $11.0M | $6.8M |
| Stock-based compensation | $7.6M | $7.4M | $8.2M | $11.1M | $9.9M |
| Capital expenditure | $5.6M | $7.5M | $6.5M | $16.7M | $34.2M |
| Free cash flow | $1.2M | $17.0M | $141.2M | $177.9M | $60.3M |
| Dividends paid | $195,000 | $715,000 | $73.0M | $71.6M | $63.9M |
| Share repurchases | $0 | $0 | $3.6M | $126.4M | $56.0M |
Shares outstanding 11.1M · Free float 72.1%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.